Myelodysplastic Syndrome clinical trials at UC Davis
6 research studies open to eligible people
CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML
open to eligible people ages 18 years and up
The purpose of this study is to test the safety of an investigational drug called CFI-400945 alone and in combination with azacitidine.
Sacramento, California and other locations
Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
open to eligible people ages 18-75
This study will evaluate the safety, tolerability, and efficacy of Orca-T, an allogeneic stem cell and T-cell immunotherapy biologic manufactured for each patient (transplant recipient) from the mobilized peripheral blood of a specific, unique…
Sacramento, California and other locations
FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation
“This study will evaluate the safety, efficacy, PK, and PD of FT-2102 as a single agent or in combination with azacitidine or cytarabine.”
open to eligible people ages 18 years and up
This Phase 1/2 study will evaluate the safety, efficacy, PK, and PD of FT-2102 (olutasidenib) as a single agent or in combination with azacitidine or cytarabine. The Phase 1 stage of the study is split into 2 distinct parts: a dose escalation part,…
Sacramento, California and other locations
Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)
open to eligible people ages 18 years and up
The primary objective of this study is to evaluate the efficacy of magrolimab in combination with azacitidine compared to that of azacitidine plus placebo in previously untreated participants with intermediate/high/very high risk myelodysplastic…
Sacramento, California and other locations
Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
open to eligible people ages 18 years and up
This is an open-label, multi-center Phase 1 study of LY3410738, an oral, covalent isocitrate dehydrogenase (IDH) inhibitor, in patients with IDH1 and/or IDH2-mutant advanced hematologic malignancies who may have received standard therapy
Sacramento, California and other locations
Collection of Tissue Samples for Cancer Research
“Collection of samples (cancerous tissue, normal tissue, blood) and related medical information for use in cancer research”
open to eligible people ages 2 months and up
Background: -Patients who are being evaluated and/or treated at the NIH Clinical Center and adult patients at participating sites will be entered onto this tissue procurement protocol for collection of tissue specimens. Objectives: - To obtain…
Sacramento, California and other locations
Last updated: